Latest Pharma Insights
BD Completes Waters Deal, Deploys $4bn Proceeds To Buybacks And Debt Reduction
Waters will apply its commercial execution model to the spun-off BD business to drive efficiencies across sales, service, product launches and digital channels.
Medtech Insight - February 13, 2026
Waters will apply its commercial execution model to the spun-off BD business to drive efficiencies across sales, service, product launches and digital channels.
Medtech Insight - February 13, 2026
US Consumer Health Industry Hires: Edible Brands, Happyactually, Nowadays, RäFoods, DoTerra, More
NPA appoints SVP membership; Edible Brands promotes Angela Johnson to CMO; happyactually has medical chief; Nowadays adds reg affairs director; doTerra appoints EVP, innovation; RäFoods names president/CEO; Genesis Lifestyle Medicine adds VP operations; and Hany Salama leads Nutra-Med Packaging.
HBW Insight - February 13, 2026
NPA appoints SVP membership; Edible Brands promotes Angela Johnson to CMO; happyactually has medical chief; Nowadays adds reg affairs director; doTerra appoints EVP, innovation; RäFoods names president/CEO; Genesis Lifestyle Medicine adds VP operations; and Hany Salama leads Nutra-Med Packaging.
HBW Insight - February 13, 2026
Japan Q3 Roundup: Weak Yen Boosts Solid Overseas Growth For Mainstays
Major Japanese pharma companies' results for the period ended Dec.31 were marked by generally strong overseas growth for mainstays, boosted by currency effects.
Scrip - February 13, 2026
Major Japanese pharma companies' results for the period ended Dec.31 were marked by generally strong overseas growth for mainstays, boosted by currency effects.
Scrip - February 13, 2026
Japan Q3 Roundup: Weak Yen Boosts Solid Overseas Growth For Mainstays
Major Japanese pharma companies' results for the period ended Dec.31 were marked by generally strong overseas growth for mainstays, boosted by currency effects.
Scrip - February 13, 2026
Major Japanese pharma companies' results for the period ended Dec.31 were marked by generally strong overseas growth for mainstays, boosted by currency effects.
Scrip - February 13, 2026
BD Completes Waters Deal, Deploys $4bn Proceeds To Buybacks And Debt Reduction
Waters will apply its commercial execution model to the spun-off BD business to drive efficiencies across sales, service, product launches and digital channels.
Medtech Insight - February 13, 2026
Waters will apply its commercial execution model to the spun-off BD business to drive efficiencies across sales, service, product launches and digital channels.
Medtech Insight - February 13, 2026
US Consumer Health Industry Hires: Edible Brands, Happyactually, Nowadays, RäFoods, DoTerra, More
NPA appoints SVP membership; Edible Brands promotes Angela Johnson to CMO; happyactually has medical chief; Nowadays adds reg affairs director; doTerra appoints EVP, innovation; RäFoods names president/CEO; Genesis Lifestyle Medicine adds VP operations; and Hany Salama leads Nutra-Med Packaging.
HBW Insight - February 13, 2026
NPA appoints SVP membership; Edible Brands promotes Angela Johnson to CMO; happyactually has medical chief; Nowadays adds reg affairs director; doTerra appoints EVP, innovation; RäFoods names president/CEO; Genesis Lifestyle Medicine adds VP operations; and Hany Salama leads Nutra-Med Packaging.
HBW Insight - February 13, 2026
Win Or Loss? Zydus Follows Lupin In Mirabegron Suit Settlement With Astellas
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Generics Bulletin - February 12, 2026
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Generics Bulletin - February 12, 2026
Samsung Bioepis Secures US Launch Date For Eylea Biosimilar – Though Later Than Others
Samsung Bioepis has signed off on another settlement for its Eylea biosimilar rival, opening up the US market from the start of 2027. While later than other competitors, for Bioepis this marks the resolution of all patent-related matters.
Generics Bulletin - February 12, 2026
Samsung Bioepis has signed off on another settlement for its Eylea biosimilar rival, opening up the US market from the start of 2027. While later than other competitors, for Bioepis this marks the resolution of all patent-related matters.
Generics Bulletin - February 12, 2026
Five Years To Go: Spotlight On Biosimilar Dupixent
With roughly five years until key exclusivities begin to expire, Generics Bulletin examines how the race to develop biosimilar versions of Dupixent is beginning to take shape.
Generics Bulletin - February 12, 2026
With roughly five years until key exclusivities begin to expire, Generics Bulletin examines how the race to develop biosimilar versions of Dupixent is beginning to take shape.
Generics Bulletin - February 12, 2026
Aspire Picks Up Irish Asset With Caragen Acquisition
UK generics firm Aspire has made another acquisition aimed at broadening its international footprint, this time buying Irish distributor Caragen.
Generics Bulletin - February 12, 2026
UK generics firm Aspire has made another acquisition aimed at broadening its international footprint, this time buying Irish distributor Caragen.
Generics Bulletin - February 12, 2026
Deals Of The Year 2025 Winners Revealed
For In Vivo's 18th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In Vivo - February 12, 2026
For In Vivo's 18th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
In Vivo - February 12, 2026
Podcast: Preventing Lung Disease In Preterm Babies
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
In Vivo - February 12, 2026
Airway Therapeutics' surfactant protein D replacement therapy showed promising Phase Ib results in preventing bronchopulmonary dysplasia, now advancing to Phase II/III registration trial in preterm infants.
In Vivo - February 12, 2026